CEO Hanna Sjöström presented GPX Medical at Life Science Day in Gothenburg March 4th to 140 Swedish life science investors.

GPX Medical has set the foundation for commercialization of a new unique medical device for lung monitoring of preterm born infants with great potential on the Global market for neonatal care. The market potential is substantial, one out of ten infants are born preterm.

GPX Medical’s medical device, Neola, targets preterm born infants with respiratory problems. The company has had promising results from three studies with 32 newborns.

-We are planning for a CE-marked Neola in 2023, says Hanna Sjöström. The company has a parallell process with FDA to be able to sell in the U.S.